JL Mag Rare-Earth (300748.SZ) plans to implement a green intelligent manufacturing project for the annual production of 20,000 tons of high-performance rare-earth permanent magnet materials, with an investment of 1.05 billion yuan.
Jinli Permanent Magnet (300748.SZ) Announcement, the company plans to establish a wholly-owned subsidiary Jinli Permanent Magnet (Baotou) Technology Co., Ltd.
Announcement of Jl Mag Rare-Earth (300748.SZ): The company plans to invest in the construction of the "annual production of 20,000 tons of high-performance rare earth permanent magnet material green intelligent manufacturing project" through its wholly-owned subsidiary Jl Mag Rare-Earth (Baotou) Technology Co., Ltd. (referred to as "Jinli Baotou Company"). The total planned investment for the project is 1.05 billion yuan, with a construction period of 2 years. After completion, the company will have an annual production capacity of 60,000 tons of high-performance rare earth permanent magnet materials.
The announcement stated that the construction of this project is an important measure for the company to further consolidate its group production capacity, improve its industrial layout, expand the company's business scale, and meet customers' order demands in the field of new energy vehicles, frequency conversion air conditioning, and Siasun Robot & Automation in the new energy and energy conservation and environmental protection sectors.
Related Articles

MINIMAX-WP(00100): Hong Kong public offering receives 1837.17 times oversubscription

Golden Resources Development Limited (03636): The public sale in Hong Kong received 143.46 times oversubscription. The sale price per share is 30 Hong Kong dollars.

Sino Biopharmaceutical - B (06938): Hong Kong public offering receives 101.06 times oversubscription.
MINIMAX-WP(00100): Hong Kong public offering receives 1837.17 times oversubscription

Golden Resources Development Limited (03636): The public sale in Hong Kong received 143.46 times oversubscription. The sale price per share is 30 Hong Kong dollars.

Sino Biopharmaceutical - B (06938): Hong Kong public offering receives 101.06 times oversubscription.

RECOMMEND

Bank Of America Sees Three Drivers Supporting Chinese Consumer Stocks: Low Base, Deep Undervaluation, And Convertible‑Like Defensive Traits
07/01/2026

Cross‑Border E‑Commerce In 2025: Tariffs, Trade Wars, And Shifting Away From The United States
07/01/2026

Asian Stock Markets Record The Strongest Annual Start Ever As Shanghai Composite Hits Multi‑Year High And Sets Longest Winning Streak; Japan And Korea Rally
07/01/2026


